|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/10/17 Evolutionary Genomics, Inc. 10-K 12/31/16 66:3.8M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Quarterly Report HTML 519K
3: EX-10.10 Agreement Amendment #2 HTML 37K
2: EX-10.9 Agreement Amendment #1 HTML 23K
4: EX-21.1 Subsidiaries List HTML 18K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
15: R1 Document and Entity Information HTML 46K
16: R2 Consolidated Balance Sheets HTML 94K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
18: R4 Consolidated Statements of Operations HTML 62K
19: R5 Consolidated Statement of Stockholders' Equity HTML 62K
20: R6 Consolidated Statements of Cash Flows HTML 84K
21: R7 Business Activity HTML 25K
22: R8 Summary of Significant Accounting Policies HTML 35K
23: R9 New Accounting Standards HTML 31K
24: R10 Fair Value Measurements HTML 43K
25: R11 Property and Equipment HTML 32K
26: R12 Intangible Assets HTML 31K
27: R13 Income Taxes HTML 50K
28: R14 Stockholders' Equity and Warrants HTML 52K
29: R15 Stock-Based Compensation HTML 68K
30: R16 Commitments and Contingencies HTML 26K
31: R17 Related Parties and Transactions HTML 23K
32: R18 Concentrations HTML 24K
33: R19 Agreement and Plan of Merger HTML 41K
34: R20 Summary of Significant Accounting Policies HTML 87K
(Policies)
35: R21 Fair Value Measurements (Tables) HTML 38K
36: R22 Property and Equipment (Tables) HTML 30K
37: R23 Intangible Assets (Tables) HTML 28K
38: R24 Income Taxes (Tables) HTML 48K
39: R25 Stockholders' Equity and Warrants (Tables) HTML 40K
40: R26 Stock-Based Compensation (Tables) HTML 66K
41: R27 Agreement and Plan of Merger (Tables) HTML 35K
42: R28 Business Activity (Details) HTML 27K
43: R29 Summary of Significant Accounting Policies (Other) HTML 24K
(Details)
44: R30 Summary of Significant Accounting Policies HTML 24K
(Property and Equipment) (Details)
45: R31 Summary of Significant Accounting Policies HTML 23K
(Intangilbe Assets) (Details)
46: R32 Summary of Significant Accounting Policies HTML 24K
(Investment in VetDC, Inc.) (Details)
47: R33 Summary of Significant Accounting Policies (Net HTML 29K
Loss Per Common Share) (Details)
48: R34 Fair Value Measurements (Details) HTML 32K
49: R35 Property and Equipment (Details) HTML 37K
50: R36 Intangible Assets (Details) HTML 48K
51: R37 Income Taxes (Narrative) (Details) HTML 29K
52: R38 Income Taxes (Income Tax Reconciliation) (Details) HTML 42K
53: R39 Income Taxes (Schedule of Deferred Tax Assets and HTML 42K
Liabilities) (Details)
54: R40 Stockholders' Equity and Warrants (Narrative) HTML 38K
(Details)
55: R41 Stockholders' Equity and Warrants (Summary of HTML 43K
Warrants Activity) (Details)
56: R42 Stock-Based Compensation (Narrative) (Details) HTML 45K
57: R43 Stock-Based Compensation (Summary of Stock Options HTML 57K
Activity) (Details)
58: R44 Commitments and Contingencies (Details) HTML 27K
59: R45 Related Parties and Transactions (Details) HTML 23K
60: R46 Concentrations (Details) HTML 30K
61: R47 Agreement and Plan of Merger (Narrative) (Details) HTML 46K
62: R48 Agreement and Plan of Merger (Purchase Price HTML 30K
Allocation) (Details)
63: R49 Agreement and Plan of Merger (Unaudited Proforma HTML 25K
Information) (Details)
65: XML IDEA XML File -- Filing Summary XML 111K
64: EXCEL IDEA Workbook of Financial Reports XLSX 51K
9: EX-101.INS XBRL Instance -- fnam-20161231 XML 735K
11: EX-101.CAL XBRL Calculations -- fnam-20161231_cal XML 139K
12: EX-101.DEF XBRL Definitions -- fnam-20161231_def XML 279K
13: EX-101.LAB XBRL Labels -- fnam-20161231_lab XML 680K
14: EX-101.PRE XBRL Presentations -- fnam-20161231_pre XML 511K
10: EX-101.SCH XBRL Schema -- fnam-20161231 XSD 102K
66: ZIP XBRL Zipped Folder -- 0001553350-17-000164-xbrl Zip 83K
| Certification |
EXHIBIT 31.1
CERTIFICATION
I, Steve Warnecke, certify that:
1. I have reviewed this annual report on Form 10-K of Evolutionary Genomics, Inc.
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting .
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| |
|
|
BY: | /s/ Steve Warnecke |
| |
| Chief Executive Officer |
| (principal executive officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/10/17 | None on these Dates | ||
| For Period end: | 12/31/16 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/23 Evolutionary Genomics, Inc. 10-K 12/31/22 58:3.3M Edgar Filing LLC/FA 3/22/22 Evolutionary Genomics, Inc. 10-K 12/31/21 56:3.2M Edgar Filing LLC/FA 3/31/21 Evolutionary Genomics, Inc. 10-K 12/31/20 61:3.3M Edgar Filing LLC/FA |